Please send us your submissions for Classifieds using the form below, this column.


Classified Positions Available

ST. PETER'S HOSPITAL, a member of St. Peter’s Health Partners, located in Albany, NY, is seeking a full time Addiction Medicine physician to join its established and respected team. The position provides inpatient addiction medicine (detoxification/rehabilitation) and medical management services in our 18 bed inpatient unit with midlevel provider support.  

Candidates should be board certified in IM/FP and possess at least one year of direct experience with addiction medicine. Certification in the administration of Suboxone is required. ASAM/ABAM certification is strongly preferred and will be required within one year of hire if not already obtained.  

The position offers a competitive salary and benefits package including: health/vision/dental, paid malpractice, 30 days paid leave annually with carry over and buy out options, CME allowance & dedicated time off, 403(b) and cash pension programs.

Albany is a medium sized city offering all the amenities of a larger city in a beautiful, scenic, and affordable setting. Albany has excellent year-round outdoor recreation, including great golf, water-sports, camping, hiking, and great skiing. Albany offers a wealth of cultural offerings and activities, including several renowned museums and theaters, fine dining, and a year-round events calendar of music and sporting events. Excellent public and private schools are available, as are affordable homes and reasonable taxes. Albany is a short drive from beautiful Saratoga Springs, the scenic Adirondack, Berkshire, and Catskill Mountains, and is part of New York’s Historic Hudson and Mohawk Valleys. Centrally located, Albany is less then three hours from New York City and Boston.

Find out more and apply online at

These are not  J-1 or H1-B opportunities

This form does not yet contain any fields.

    Member News

    Please send us your submissions for Member News using the form below, right column.


    NYSAM News


    Amphetamines: Not Just for Kids Anymore

    If you thought Ritalin was invented in the early 00s - when every hyperactive American kid popped a few mills with his Cap'n Crunch and zipped off to 4th grade homeroom - you wouldn't be alone. But methylphenidate has been around as a treatment for hyperactivity since at least the 60s. Then, as now, doctors were quick to give kids this legal meth when deeper emotional issues were desperately seeking diagnosis.

    In fact, fans of 1973's The Exorcist know that, before Fathers Merrin and Karras saved young Regan's soul, she was given a prescription for Ritalin. "Nobody knows the cause of hyperkinetic behavior in a child," the doctor told Ellen Burstyn's Chris MacNeil. "The Ritalin seems to work to relieve the condition." Some parents of hyperactive kids still imagine their children are possessed by demons.

    Lawrence Diller, author of Running on Ritalin, told Frontline, "Prozac was introduced in 1988. The explosion in Ritalin occurred in 1991. And I believe that Prozac paved the way, in terms of acceptability, for the use of Ritalin in children."

    Here we are, 25 years later, and the sledgehammer of Ritalin's heavy-handed speedy chemistry has given way to a new generation of more refined pharmaceutical meth. And it's no longer a drug for hyperactive kids. Writing in The Guardian, journalist (and Van Winkle's contributor) Alexander Zaitchik reports that the market for pharmaceutical stimulants in the U.S. is now majority adult.

    Thanks to the eagerness of many doctors to prescribe so-called ADHD drugs, every high school in the country is sloshing with enough amphetamine to keep five Panzer divisions awake during an extended Africa campaign. But now, for the first time, you are more likely to find drugs like Vyvanse and Adderall in a corporate office park than a classroom.

    There is something unsettling about this continuing growth in prescription stimulants. Even though the pills are as strong as street meth - which in any case metabolizes quickly into dextroamphetamine, the main active ingredient in most ADHD drugs - nobody seems to call this class of drugs by its name: "speed."

    At least part of this growth comes down to nomenclature. No respectable suburbanite would dare touch bathtub crank, but popping an addy before heading out to Bennigan's for a few brews with the boys? Where's the harm? It's a prescription. Zaitchik recounts his own conversation with a drug dealer:

    During our recent industry-guided speed renaissance, "speed" has been turned into "meds", reflecting the idea that amphetamine for most people remains some kind of safe treatment or routine performance-booster, rather than a highly addictive drug with some nasty talons in its tail. The full extent of this cultural forgetting hit me several years ago, when I asked an otherwise sophisticated street dealer what kind of speed he was holding. He stared at me in utter incomprehension. When I clarified my request with brand names, he said: "Oh, you mean meds."

    The rise of "the adult ADHD" market can largely be credited to drugmaker Shire, according to Zaitchik. From heavily funded conferences and studies to blatant direct-marketing campaigns featuring celebrity spokesdouches, Shire is pushing aggressively for wider acceptance. Zaitchik writes, "In January, Shire won FDA approval to prescribe its leading patented stimulant, Vyvanse, as a treatment for 'binge eating,' suggesting a return to the post-Cold War decades when the 'Dexedrine Diet' turned millions of women in the US and Europe into amphetamine addicts."

    It's a particularly vicious cycle, as Zaitchik notes.

    Many people signing up for Vyvanse and other new-gen daily regimen speeds are happy to buy into this illusion of distance between past and present, between street dealer and doctor's pad. Poor people do dirty drugs like "meth" and "speed" and ruin their lives. Middle class strivers do "meds" and succeed while slimming down. But the truth is all speed is addictive. And all speed, even elegantly designed concoctions like Vyvanse, leaves users crashed out and riddled with anxiety and depression that deepens with time. (As those crashes get worse, it's worth noting, they increase the allure of prescription opiates and benzodiazepines - two other booming drug markets that pharma has done much to cultivate.)

    Who's coming out on top? The drug-makers, of course. Like an arms dealer selling to both sides of a civil war, Big Pharma is happy to peddle both the disease and cure.

    Grown men and women are welcome to use whatever drugs they want, provided they're not jeopardizing the lives of others. (Of course, what exactly constitutes "jeopardizing" is up for debate. I happen to be exceptionally liberal in these matters; just stay off the road.) Whether you want to get more shit done at work, or need a few pills to survive a family reunion - have at it.

    But if you're taking comfort in Adderall's legal status, denying its chemical relations to bathtub crank favored by toothless speed freaks, you're kidding yourself.

    -- Jeff Koyen

    From Van Winkle's website on the Huffington Post


    Ottawa to tackle opioid abuse with tamper-resistance rules 

    The Globe and Mail

    The federal government is introducing new tamper-resistance rules for opioid painkillers aimed at reducing prescription-drug abuse.

    On Friday, Health Canada announced draft regulations that would require all oxycodone products to be “tamper-resistant” before they can be sold. Tamper-resistant refers to drugs that are difficult to crush, snort or inject as a way of preventing people from getting high. The new rules are designed to help combat the growing problem of opioid misuse and abuse in Canada, which has the world’s second-highest per capita consumption of the drugs, which include oxycodone, fentanyl and morphine.

    Prescription pill bottle containing oxycodone and acetaminophen are shown in this June 20, 2012 photo. The Canadian Press

    From morphine to ‘hillbilly heroin’

    “Prescription-drug abuse is a significant public-health and safety concern,” Health Minister Rona Ambrose said in a statement. “Adding tamper-resistant properties to drugs at high risk of abuse is an important component of our government’s comprehensive approach to fighting prescription-drug abuse.”

    The proposed rules include a three-year phase-in period to allow companies to reformulate products. If companies do not reformulate products in that time period, they will not be allowed to sell them in Canada.

    But prominent Canadian medical organizations and experts are concerned the government’s push toward tamper-resistance is deeply flawed. The scientific evidence defining tamper resistance and whether it actually works at reducing rates of abuse is still relatively new. And the regulations would apply only to one type of opioid, which could simply shift the problem elsewhere.

    The only way the government’s new rules will have any impact is if the tamper-resistance requirements are extended to all opioids, said Dr. Chris Simpson, president of the Canadian Medical Association.

    “If you create a deterrent for one drug, then people just move to other drugs that don’t have that technology,” he said in an interview.

    In its official submission to Health Canada last year on the proposed new rules, the Canadian Pharmacists Association urged the federal government not to single out a single drug category for tamper-resistance requirements, in order “to prevent drug abusers from switching to another” drug.

    And tamper-resistance targets only a subset of opioid users, namely those who abuse drugs by snorting, chewing or injecting.

    “That’s the only element that tamper resistance addresses,” said Phil Emberley, director of pharmacy innovation at the Canadian Pharmacists Association. “Those people that get large quantities of this drug and take it by mouth, tamper-resistance is not going to change that.”

    In addition to the new regulations, the federal government has also launched a national marketing campaign to help parents talk to their children about prescription-drug abuse and has set aside funds to address the problem, including $13.5-million over five years to help First Nations communities and $8-million for prescriber education programs and the development of a national monitoring and surveillance program.


    Treating Tobacco Use Online Learning Module for Health Care Providers 

    The New York City Health Department has developed an interactive, online learning module entitled, Treating Tobacco Use to enhance provider knowledge on how to effectively assess, counsel and treat tobacco use. As the leading cause of preventable death in the U.S., we as health care professionals are in a prime position to help our patients successfully quit tobacco, while simultaneously lowering their risk of heart disease, stroke, COPD and other diseases. 

    A detailed description of the course is attached, but highlights of the module include:

    •   The “5 A’s” model of treating tobacco use
    •   Provider/Patient communication techniques
    •   Treatment options and guidance, including combination therapy
    •   New York State Medicaid Benefits
    •   Billing information for smoking cessation counseling

    By incorporating this module into your continued education, providers – including those in training – will have the tools and resources needed to counsel and prescribe for tobacco use thereby greatly improving patients’ chances of successfully quitting. For medical residents, this module meets five of six Accreditation Council for Graduate Medical Education (ACGME) core competencies and can be placed into your learning management system. For physicians, the module provides 1 CME credit

    Click here to access the online module (note, there is no audio) and here to access additional provider resources.

    Once patients receive treatment, they can also visit and search NYC QUITS to access tools and information on how to quit and stay quit.

    We hope you find this learning module useful.  If you have questions or would like to learn more about how to incorporate the learning module into your learning management system, please contact us at 347-396-4552.


    Mark Bansfield, MPH CTTS CHES



    Overview of Opioid Overdose Prevention Programs in New York State


    Opioid overdose is a significant problem across the country including New York State. Widespread misuse of prescription opioids and heroin continues to be a serious problem.  One tool in preventing opioid overdose morbidity and mortality is increasing access to naloxone.

    Naloxone (Narcan) is a prescription medicine that reverses an overdose by blocking heroin or other opioids in the nervous system for 30 to 90 minutes. Naloxone is administered by injection or intranasally. It is successfully prescribed and distributed to opioid users, their families and friends in at least 19 states.  Thousands of individuals participating in these programs have safely and successfully reversed overdoses. As of the end of 2010 over 50,000 people in the United States had received naloxone kits and over 10,000 overdose reversals had been reported. 

    A new life-saving law took effect in 2006, making it legal in New York State for non-medical persons to administer naloxone to another individual to prevent an opioid/heroin overdose from becoming fatal.  The New York State Department of Health (NYSDOH) registers eligible agencies and providers to operate an Opioid Overdose Prevention Program and provides the required supplies for free.  These programs train individuals how to respond to suspected overdoses including the administration of naloxone, which is provided free as part of the training.


    • Registration with the NYSDOH authorizes physicians, Nurse Practitioners and Physician
      Assistants to prescribe naloxone to people at risk of witnessing an overdose and authorizes an agency (or individual clinician) to order free intramuscular naloxone kits from the NYSDOH.
    • Each opioid overdose program must have a program director and a clinical director who are responsible for complying with the program requirements and insuring the quality of the training performed by the agency.  The clinical director must be an MD, PA, or NP.  Agencies that do not have medical providers on staff may hire someone for this function for a limited number of hours. 
    • Sample policy and procedures are available to simplify integration into an agencies existing policy and procedures.
    • Any competent staff member or volunteer can do the training on overdose prevention and response; the prescribing clinician need not be present. Train the Trainer sessions are available as is an educational curriculum.
    • Naloxone is a prescription medication, thus governed by NYS prescribing regulations.  The prescribing clinician must have a face to face encounter with each recipient, provide a prescription (serving as a label) and a record of the recipients identifying information as well as a note that the recipient has been trained.  This can be done in less than a minute. Prescription medications may only be dispensed by a licensed prescriber, nurse or pharmacist.
    • Agencies in New York City may register with the New York City Department of Health and Mental Hygiene in order to be eligible to order free intranasal naloxone kits.

    Implementation varies among agencies according to their needs and settings (syringe access programs, drug treatment programs, primary care, in-patient hospital units, etc.).  Trainings can be tailored to individuals, groups, or classrooms, and may vary in length from 10 - 50 minutes.  A 12 minute DVD can be used supplemented by hands on demonstration.

    The Harm Reduction Coalition works under contract with the NYSDOH to provide assistance in implementing opioid overdose prevention programs. We can help by training staff, discussing the application for NYSDOH registration, and helping to determine training needs of staff and clients.  

    Contact the Harm Reduction Coalition: for more information and assistance in establishing an overdose prevention program:

    Sharon Stancliff, MD: 
    (212) 213-6376 ext 39

    Bill Matthews, RPA-C:
    (212) 213-6376 ext 38

    Overdose prevention resources

    Harm Reduction Coalition

    Many resources under “Overdose”

    New York State Department of Health

    Includes sample curriculum, policy & procedures, a list of registered agencies

    New York City Department of Health and Mental Hygiene


    The NYCDOH&MH training video is easily seen here:







    Do You Want to Learn More About Managing Chronic Opioid Therapy and Addiction? Participate in This NIH-Funded Research Study 


    Inflexxion® develops behavioral change programs that reduce health-related risks, improve clinical outcomes and positively influence quality of care and improve public health. Please choose the research study that interests you and click the corresponding link for more information. If you are eligible for a study a Research Coordinator will contact you. If you have questions about these studies, or would like to speak with someone, please call 617-332-6028 anytime Monday through Friday 9:00am to 5:00pm EST.

    Current Studies:

    MAP-PC Field Trial

    Do you want to learn more about managing chronic opioid therapy and addiction?

    Participate in our NIH-Funded research study!

    This study is being funded by the National Institutes of Health (NIH) and will evaluate knowledge, behaviors, and attitudes about managing chronic pain and addiction in a primary care setting. We are currently looking for physicians, residents, fellows, nurses, nurse practitioners or physician assistants who are currently practicing in a primary care setting, and are a currently-licensed prescriber of prescription pain medications.  Participants will complete one of two online programs focused on provider management of chronic non-cancer pain with chronic opioid therapy. Participants will take approximately 4 hours to complete the online course on their own at times and locations of their convenience.   


    Opioid management is a challenging area of primary care.  With new requirements for education on the horizon, there is increasing need for providers to be knowledgeable in this area. The online programs in this study teach ways to efficiently and effectively manage pain care by:

    Assessing  and managingdifficult patients

    Identifying appropriate patients for referral

    Maximizing medical team resources

    Enhancing patient compliance with treatment and monitoring regimens


    Participants will receive an honorarium of up to $300 if they complete all study tasks.

    Feel free to invite your colleagues to participate in this study!

    If you are interested in participating in the study, please click the following link to learn more.

    If you have any questions, please contact the research coordinator, Cristina Los, or 617-775-7873.